If the control arm doesn't over perform, you may be surprised by the results. In phase 2 the control arm smashed the Marina results (same drug). The main endpoint is patients with minimally classic and occult - RAP absent. I expect a minimum 6 letter improvement. Overall, maybe 4+. There is no point focussing on the overall population as Sozinibercept is ineffective in RAP affected patients. I'll take a 6 letter improvement in the subgroup (about 75% of patients).
Add to My Watchlist
What is My Watchlist?